Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA

Journal of Infectious Diseases

Volumn 185, Issue 10, 2002, Pages 1388-1394

  Tripp, Ralph A ^a   Moore, Deborah ^a   Barskey, Albert ^a   Jones, Les ^a   Moscatiello, Caminade ^b   Keyserling, Harry ^b   Anderson, Larry J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD16 ANTIGEN; CD56 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; RANTES;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFANT; MALE; MONONUCLEAR CELL; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TH1 CELL; TH2 CELL; VIRUS INFECTION;

CHEMOKINES, CC; CYTOKINES; FEMALE; FLOW CYTOMETRY; HOSPITALIZATION; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; RANTES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, MESSENGER; TH1 CELLS; TH2 CELLS;

EID: 0037093970     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340505     Document Type: Article

References (62)

1. Respiratory syncytial viruses
2. Serious respiratory tract disease caused by respiratory syncytial virus: Prospects for improved therapy and effective immunization
3. Respiratory syncytial virus infection
4. Respiratory syncytial virus infection in children with congenital heart disease: A review
5. Bronchiolitis-associated hospitalizations among US children, 1980-1996
6. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997
7. Bronchiolitis in infants
8. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children
9. Wheezing following lower respiratory tract infections with respiratory syncytial virus and influenza A in infancy
10. Novel pathways in the pathogenesis of respiratory syncytial virus disease
11. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived
12. Respiratory syncytial virus vaccine development
13. Role of cytokines in determining T lymphocyte function
14. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations
15. Chemokines and innate immunity
16. Dancing to the tune of chemokines
17. Chemokines as regulators of T cell differentiation
18. Regulation of Th1 and Th2 immune responses by chemokines
19. Immune chemokines and their receptors: The key elements in the genesis, homeostasis and function of the immune system
20. Chemokines. Introduction
21. T cell chemokine receptor expression in human Th1- and Th2-associated diseases
22. Chemokines and other mediators, 8. Chemokines and their receptors in cell-mediated immune responses in the lung
23. Chemokines: Immunology's high impact factors
24. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent
25. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection
26. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus
27. TH(1)- and TH(2)-TYPE cytokine expression by activated t lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus
28. Respiratory syncytial virus G and/or SH protein alters Th 1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice
29. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism
30. Immunity and immunopathology to respiratory syncyrial virus. The mouse model
31. Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine
32. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population
33. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia
34. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses
35. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus
36. Respiratory syncytial virus G and/or SH gtycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse
37. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
38. Structure and function of the CD16:zeta:gamma complex expressed on human natural-killer cells
39. Function of human Fc gamma RIIA and Fc gamma RIIIB
40. Specific functions of human NK cells
41. Human natural killer cells
42. Activated T cells and cytokine-induced CD3+CD56+ killer cells
43. Role of human natural killer cells in health and disease
44. The biology of human natural killer-cell subsets
45. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset
46. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire
47. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: A comparative study
48. Surfactant protein A binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity
49. Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells
50. The development of CD4+ T effector cells during the type 2 immune response
51. Cellular responses to interferon-gamma
52. Respiratory syncytial virus infection: Its role in aeroallergen sensitization during the first two years of life
53. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms
54. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness
55. Induction of allergen-specific IL-2 responsiveness of lymphocytes after respiratory syncytial virus infection and prediction of onset of recurrent wheezing and bronchial asthma
56. Respiratory syncytial virus infection prolongs methacholine-induced airway hyper-responsiveness in ovalbumin-sensitized mice
57. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
58. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent
59. CCR5 is characteristic of Th1 lymphocytes
60. Th1/Th2 subsets: Distinct differences in homing and chemokine receptor expression?
61. CC chemokines induce the generation of killer cells from CD56+ cells
62. Natural killer cells in antiviral defense: Function and regulation by innate cytokines